iRhythm Technologies Announces Retirement of Two Board Members

By Philip Seaworth • Tuesday, July 08 15:23 • Permanent Link

iRhythm Technologies, Inc. (NASDAQ:IRTC) has announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors.

Mark Rubash served on the board since 2016 and brought decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, brought unparalleled clinical expertise. Both leaders decided to leave the board to pursue personal endeavors in their retirement.

iRhythm’s newly appointed board members, Karen McGinnis and Kevin O’Boyle, bring deep financial expertise, business acumen, and strategic operational experience from within the medical and biotechnology industry.

Karen McGinnis has over three decades of experience leading complex international companies across biotechnology, consumer electronics, semiconductor, and technology industries. Her most recent executive role was Chief Accounting Officer at Illumina, Inc. (NASDAQ: ILMN) from 2017 to 2021.

Kevin O'Boyle brings over 20 years of executive leadership experience, most notably as Executive Vice President and Chief Financial Officer at NuVasive, where he helped grow the company's market capitalization from $100 million to $2 billion.

The press release also emphasizes the gratitude to Mark and Ralph for their service, wisdom, and steadfast leadership during a crucial period of company maturation while welcoming Karen and Kevin, whose extensive experiences and global expertise will be invaluable as iRhythm enters its next phase of growth.

Following these announcements, the company's shares moved -2.67%, and are now trading at a price of $135.50. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.